COLLABORATION AND LICENSE AGREEMENT by and between IGM BIOSCIENCES, INC. and GENZYME CORPORATION dated as of March 28, 2022Collaboration and License Agreement • March 29th, 2022 • IGM Biosciences, Inc. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of March 28, 2022 (the “Execution Date”) by and between IGM Biosciences, Inc., a corporation organized and existing under the laws of Delaware (“IGM”) and Genzyme Corporation, a corporation organized under the laws of Massachusetts, with its principal business address at 450 Water St, Cambridge, MA 02141 (“Sanofi”). IGM and Sanofi are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
